These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 29107218)
1. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer. Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218 [TBL] [Abstract][Full Text] [Related]
2. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery. Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645 [TBL] [Abstract][Full Text] [Related]
3. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412 [TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA. Tarighi P; Khorramizadeh M; Madadkar-Sobhani A; Ostad S; Ghahremani M Acta Med Iran; 2015 Jul; 53(7):403-7. PubMed ID: 26520626 [TBL] [Abstract][Full Text] [Related]
5. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258 [TBL] [Abstract][Full Text] [Related]
6. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. Lee GY; Qian WP; Wang L; Wang YA; Staley CA; Satpathy M; Nie S; Mao H; Yang L ACS Nano; 2013 Mar; 7(3):2078-89. PubMed ID: 23402593 [TBL] [Abstract][Full Text] [Related]
7. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. LeBeau AM; Sevillano N; King ML; Duriseti S; Murphy ST; Craik CS; Murphy LL; VanBrocklin HF Theranostics; 2014; 4(3):267-79. PubMed ID: 24505235 [TBL] [Abstract][Full Text] [Related]
8. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. Gutova M; Najbauer J; Gevorgyan A; Metz MZ; Weng Y; Shih CC; Aboody KS PLoS One; 2007 Feb; 2(2):e243. PubMed ID: 17327908 [TBL] [Abstract][Full Text] [Related]
9. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518 [TBL] [Abstract][Full Text] [Related]
10. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
11. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells. Moreau M; Mourah S; Dosquet C Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943 [TBL] [Abstract][Full Text] [Related]
12. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging. Tan Y; Cao Z; Sajja HK; Lipowska M; Wang YA; Yang L; Jiang H J Xray Sci Technol; 2013; 21(1):43-52. PubMed ID: 23507851 [TBL] [Abstract][Full Text] [Related]
13. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Ke XY; Lin Ng VW; Gao SJ; Tong YW; Hedrick JL; Yang YY Biomaterials; 2014 Jan; 35(3):1096-108. PubMed ID: 24183698 [TBL] [Abstract][Full Text] [Related]
14. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer. Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758 [TBL] [Abstract][Full Text] [Related]
16. Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Ahmed MSU; Salam AB; Yates C; Willian K; Jaynes J; Turner T; Abdalla MO Int J Nanomedicine; 2017; 12():6973-6984. PubMed ID: 29033565 [TBL] [Abstract][Full Text] [Related]
17. The effect of mechanical properties of iron oxide nanoparticle-loaded functional nano-carrier on tumor targeting and imaging. Choi WI; Kim JY; Heo SU; Jeong YY; Kim YH; Tae G J Control Release; 2012 Sep; 162(2):267-75. PubMed ID: 22824783 [TBL] [Abstract][Full Text] [Related]
18. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
19. Killing Glioma 'Stem-like' Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins. Gorin FA; Pasupuleti N; Mahajan D; Dugar S Anticancer Agents Med Chem; 2017; 17(1):40-47. PubMed ID: 27357540 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]